ClinicalTrials.gg
CompletedNCT03713671Updated Dec 5, 2023

Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism

An interventional study of gait analysis in Primary Hyperparathyroidism, sponsored by Recep Tayyip Erdogan University Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-05.

Sponsored by Recep Tayyip Erdogan University Training and Research Hospital · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
All
01

Study summary

This study will evaluate how Quadriceps Femoris muscle fatigue protocol affect the spatio-temporal gait parameters, gait symmetry and balance in individuals with primary hyperparathyroidism before and after parathyroidectomy. Study group will consist of 20 subjects with primary hyperparathyroidism (PHPT) and control group will consist of 20 healthy subjects.

Read the detailed description

Parathyroid hormone, released from the parathyroid gland, plays an important role in keeping the ionized calcium in between the reference values in body. Precise control of ionized calcium is particularly necessary to ensure the optimal function of physiological processes such as providing intracellular signaling, performing neuromuscular functions and bone metabolism. When there is a decrease in the level of ionized calcium in the systemic circulation due to any reason, increased calcium concentration is maintained as a result of the increased absorption of calcium from the kidneys, bones and intestines into the blood via increased parathyroid hormone. An error caused by any of the components in this regulatory system may cause excessive parathyroid hormone release, causing primary, secondary or tertiary hyperparathyroidism. Primary hyperparathyroidism (PHPT) is a common endocrinological disorder, which is characterized by excessive release of parathyroid hormone, resulting in a defect in the regulation of calcium metabolism. PHPT, is the third most common endocrine disease and is the most common cause of hypercalcemia. Today, PHPT is approximately 0.25-0.66% of the population and it is seen as 3: 1 times more common in women than men. While the incidence of the disease increases with age, it increases dramatically after 50 years of age. The clinical presentation of PHPT ranges from asymptomatic disease to the classical symptomatic disease of renal and / or musculoskeletal complications. Low plasma 25 Hydroxyvitamin D level; bone mineral density, muscle strength, preservation of postural stability and functional performance of the musculoskeletal functions such as disruption caused by the person's walking and balance activities are adversely affected.In addition, fatigue, pain, and body mass index, as a result of the increase in the functional capacity of the person is seriously reduced quality of life and psychosocial status is adversely affected. Although there are studies related to bone mineral density, muscle strength and function, instability, fatigue, etc., which are secondary to PHPT and cause a significant decrease in functional capacity, there is no study to investigate the effect of M. quadriceps Femoris ,which has a key role in the evaluation of functional capacity, muscle fatigue on the gait and balance parameters in the pre and post-treatment period in the literature. The aim of this case-control study is to investigate the effect of Quadriceps Femoris muscle fatigue protocol on gait, gait symmetry and balance parameters before and after parathyroidectomy in patients PHPT and to compare that parameters of these individuals with healthy controls with similar demographic characteristics that included in the control group.

02

Conditions studied

  • Primary Hyperparathyroidism

Keywords

  • Primary Hyperparathyroidism
  • Spatio-Temporal Parameters of Gait
  • Gait Symmetry
  • Balance
03

In context

Hyperparathyroidism, Primary

104 studies on the registry are indexed under Hyperparathyroidism, Primary; 23 are open to participants now.

This study's enrollment of 40 is below the median of 68 across 60 interventional studies indexed under Hyperparathyroidism, Primary.

Browse Hyperparathyroidism, Primary studies →

Lead sponsor

Recep Tayyip Erdogan University Training and Research Hospital is the lead sponsor of 88 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PHPT group, include cases with a Primary Hyperparathyroidism
  • Control group consists of healthy adults with the similar demographic characteristics as study group.

Exclusion criteria

Exclusion Criteria:

  • The presence of osteoarticular deformities
  • Walking with assist device
  • Having a neurological disease that may affect the performance
  • To have significant and irreversible visual deficits
  • The (BMI) is greater than> 40 kg / m²
  • There is an inability to prevent any of the tests
  • Individuals with cancer history and chemotherapy (over the last 5 years)
  • Plasma creatinine level> 150 µmol / L
  • Use of Cinacalcet or Etalpha
  • Having a history of diabetes mellitus
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Other
    PHPT Group

    Spatio-Temporal gait analysis and balance assessment of subjects with Primary Hyperparathyroidism

    Diagnostic Test: gait analysis

  • Other
    Control Group

    Spatio-Temporal gait analysis and balance assessment of healthy subjects

    Diagnostic Test: gait analysis

Interventions

  • Diagnostic testgait analysis

    Computerized gait analysis system will use to evaluate spatio-temporal gait parameters

06

What researchers measure

Primary outcomes

  1. Step Length

    It is measured along the length of the walkway, from the heel center of the current footprint to the heel center of the previous footprint on the opposite foot.The unit of measure is centimeters.

    Time frame: 1 week

Secondary outcomes

  1. Stride Length

    It is measured on the line of progression between the heel points of two consecutive footprints of the same foot (left to left, right to right). The unit of measure is centimeters.

    Time frame: 1 week

  2. Static Balance Assessment

    The Romberg test will use to assessment for diagnose sensory ataxia, a gait disturbance caused by abnormal proprioception involving information about the location of the joints. The Static Balance Assessment of the individuals in the PHPT group were assessed before and 3 months after Parathyroidectomy.

    Time frame: 1 week

  3. Dynamic Balance Assessment

    To determine fall risk and measure the progress of balance, sit to stand, and walking Timed Up and Go Test will use. The Dynamic Balance Assessment of the individuals in the PHPT group were assessed before and 3 months after Parathyroidectomy.

    Time frame: 1 week

  4. Fatigue Severity

    The fatigue level that individuals perceived during the performance was recorded using the Fatigue Severity Scale. This is a nine-items questionnaire that assesses the effect of fatigue on daily living. Each item is a statement on fatigue that the subject rates from 1, ' strongly disagree ' to 7, ' strongly agree '.

    Time frame: 1 week

  5. Functional Capacity

    6 Minute Walk test was used to evaluate the functional capacity. The test was performed in a corridor on a flat hard surface of 30 m in length in a straight line. Before the examination, the patient rested for 10 min in a sitting position. It is calculated by measuring the distance that the person walks at the end of this period by asking the person to walk for 6 minutes along a 30 m corridor. In cases of chest pain, dyspnea, leg cramps, excessive fatigue, sweating and wilting, the test should be terminated immediately. The clinician supervising the test instructed the subject on the walking technique and the possibility of taking a rest. At one-minute intervals during the test, the participant received information about the time remaining until the end of the test.

    Time frame: 1 week

  6. Step Width

    It is measured from the midline midpoint of the current footprint to the midline midpoint of the previous footprint on the opposite foot.The unit of measure is centimeters.

    Time frame: 1 week

  7. Foot Progression Angle

    It is the angle between the line of progression and the midline of the footprint. This angle is zero if the geometric mid- line of the footprint is parallel to the line of progression; positive, toe-out, when the mid-line of the footprint is outside the line of progression and negative, toe-in, when inside the line of progression. The unit of measure is degrees.

    Time frame: 1 week

  8. Speed

    It is obtained after dividing the distance traveled by the ambulation time. It is expressed in centimeters per second (cm/sec)

    Time frame: 1 week

  9. Cadence

    The rate at which a person walk, expressed in steps per minute (step/min). The average cadence is 100 - 115 steps/min.

    Time frame: 1 week

  10. Percentage of Double Support

    It is the amount of time that a person spends with both feet on the ground during one gait cycle. It is presented as a percentage of the gait cycle time (% gait cycle). The percentage of time spent in double support decreases as the speed of walking increases.

    Time frame: 1 week

  11. Percentage of Stance

    The stance phase is the weight bearing portion of each gait cycle. It is initiated by heel contact and ends with toe off of the same foot. It is the time elapsed between the first contact and the last contact of two consecutive footfalls on the same foot. It is also presented as a percentage of the gait cycle time (% gait cycle)

    Time frame: 1 week

  12. Percentage of Swing

    It is initiated with toe off and ends with heel strike. It is the time elapsed between the last contact of the current footfall to the first contact of the next footfall on the same foot. It is expressed in seconds (sec) and it is also presented as a percent of the gait cycle (% gait cycle) of the same foot. The Swing Time is equal to the Single Support time of the opposite foot.

    Time frame: 1 week

  13. Gait Symmetry

    It's calculated in order to evaluate symmetry and bilateral coordination of gait. The Symmetry Index and Symmetry Angle are interpreted as a complete symmetry if the result is 0. Evaluation of asymmetries observed in the spatio-temporal characteristics, a deviation of at least 10% from the 0 value for exact symmetry.

    Time frame: 1 week

07

Study locations

1 site
  • Ankara Education and Research Hospital
    Ankara, Cankaya 06100, Turkey (Türkiye)
08

References and documents

Publications

  • Rolighed L, Rejnmark L, Sikjaer T, Heickendorff L, Vestergaard P, Mosekilde L, Christiansen P. No beneficial effects of vitamin D supplementation on muscle function or quality of life in primary hyperparathyroidism: results from a randomized controlled trial. Eur J Endocrinol. 2015 May;172(5):609-17. doi: 10.1530/EJE-14-0940. Epub 2015 Feb 2. PubMed 25646406 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data for all primary and secondary outcome measures will be made available.

Supporting information: Study protocol, Clinical study report

Time frame: Data will be available within 6 months with completion of the result report.

Access criteria: Requestors will be required to sign a Data Access Agreement.

Data sharing details ↗ · orcid.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in May 2023, 18 months.

Of 20 interventional studies with no phase under Hyperparathyroidism, Primary, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 84. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2018
First posted
Oct 22, 2018
StartActual
Oct 17, 2021
Primary completionActual
May 15, 2023
CompletionActual
Aug 27, 2023
Last update
Dec 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03713671
Lead sponsor
Recep Tayyip Erdogan University Training and Research Hospital
Collaborators
Hacettepe University, Ankara Education and Research Hospital
Responsible party
Melek Merve ERDEM (Research Assistant, Recep Tayyip Erdogan University Training and Research Hospital) — Principal investigator
First posted
Oct 22, 2018
Start date
Oct 17, 2021
Primary completion
May 15, 2023
Completion
Aug 27, 2023
Last update
Dec 5, 2023

Study contacts

Melek M. ERDEM
principal investigator · Tayyip Erdogan University Training and Research Hospital
Gonul KOC, MD
study director · Ankara Education and Research Hospital
Semra TOPUZ, Assoc. Prof.
study director · Hacettepe University
Mikail K. DEMIREL, MD
study chair · Ankara Education and Research Hospital
Cavit CULHA, Assoc. Prof.
study chair · Ankara Education and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion